UK housing market downturn eases but sentiment remains ‘fragile’, surveyors say – business live

Brent crude dips slightly below $78 a barrel; most Asian stock markets bounce backBritain’s second-biggest drugmaker GSK has also taken a hit from recent drug failures.The Californian biotech Alector has said that GSK has ended their neuroscience collaboration covering ​two experimental antibody drugs, after both drug candidates suffered setbacks in clinical trials.The CARDIO-TTRansform trial was designed to examine the role of Wainua, a gene silencer treatment, on top of today’s standard of care in reducing recurring cardiovascular events and mortality.Although the trial did not meet its primary objective, we believe the results support greater scientific understanding of treatment approaches for the hundreds of thousands of patients worldwide suffering from this progressive and often fatal condition. Continue reading...